1. Please visit www.imd3.org for more information.
The Institute for Molecular Diversity & Drug Design (IMD3) 7th Annual Symposium In Pursuit of New Medicines: Natural & Synthetic Molecules and Their Targets Tuesday, March 22, 2005 Rudd Heart & Lung Conference Center at Jewish Hospital HealthCare Services 200 Abraham Flexner Way, Louisville, KY
8:00 AM Poster Setup & Continental Breakfast 8:30 AM Opening Remarks James L. Wittliff, Ph.D., Acting Director, IMD3 K. Grant Taylor, Ph.D., Acting Co-Director, IMD3 8:45 AM A Systems Approach to Cancer Drug Discovery: Genomics, Proteomics & Bioinformatics John N. Weinstein, M.D., Ph.D. Senior Investigator, Laboratory of Molecular Pharmacology, National Cancer Institute/NIH 9:45 AM Drug Discovery: in silico, in vitro, in vivo John O. Trent, Ph.D. Structural Biology Program, J. Graham Brown Cancer Center University of Louisville 10:15 AM Break & Poster Viewing 10:45 AM Developing Allenylic and Propargylic Fluorinating Modules for Diversity-Oriented Synthesis Gerald B. Hammond, Ph.D. Professor and University Scholar, Department of Chemistry University of Louisville 11:15 AM Protein Engineering Sterol Biosynthesis to Understand Enzyme Action and Drug Selectivity W. David Nes, Ph.D. Professor of Chemistry & Biochemistry, Texas Tech University Program Director, Molecular & Cellular Biosciences National Science Foundation 12:15 PM Closing Remarks & Poster Winners K. Grant Taylor, Ph.D. & James L. Wittliff, Ph.D. 12:30 PM Lunch Served & Poster Viewing
Please visit for more information.

2. Hormone Receptor Laboratory
Distinguished Visiting Speakers:
John N. Weinstein, M.D., Ph.D.
John Weinstein, innovative investigator at the National Cancer Institute received a B.A. degree in Biology at Harvard College and then completed the M.D. degree and a Ph.D. degree in Biophysics at Harvard University. His extensive curriculum vitae, which lists more than 200 publications mostly on new approaches to the treatment of cancer or AIDS, includes ten articles in the highly prestigious journal Science, in which he appears as first author. After an internship and residency in Medicine at Stanford Medical Center, he joined the National Institutes of Health to study biological membranes and membrane receptors. In 1975, he moved to the National Cancer Institute (NCI), where Dr. Weinstein is currently a Senior Research Investigator in the Laboratory of Molecular Pharmacology and Captain (retired), U.S. Public Health Service. He is the founder and head of the NIH Drug Discovery Interest Group and the NIH Genomics and Bioinformatics Interest Group, as well as Head of the NCI Bioinformatics, Biostatistics, and Computational Biology Faculty. Dr. Weinstein is widely sought as a speaker because of his ability to describe complex aspects of the new biology in an exciting and comprehensive manner.
W. David Nes, Ph.D.
David Nes, educator and scientist, received a B.A. degree from Gettysburg College and the M.S. degree from Drexel University before being awarded the Ph.D. degree from the University of Maryland. After serving as a Research Fellow with the world renowned steroid chemist, Erich Heffmann at the University of California-Berkeley, he studied as a BARD Fellow in the USDA Laboratories in Albany, CA and then was awarded a Visiting Scientist Fellowship at Karlsruhe University in Germany where he continued his research on natural products chemistry. He has held faculty posts at Auburn University, the University of Georgia and at Texas Tech University, where he was appointed Professor in the Department of Chemistry and Biochemistry in Currently, he serves as Program Director in the Molecular and Cellular Biosciences Division at the National Science Foundation, where he is leading the Sensors and Metabolic Engineering Programs. The laboratory of Dr. Nes is well recognized as a center for bioorganic chemistry, where more than fifty graduate students, post doctoral fellows and visiting scientists have trained.
Featured Speakers from the IMD3:
Gerald B. Hammond, Ph.D.
Professor Hammond received a B. S. Degree from Pontifica Universidad Catolica del Peru in Lima, Peru, a M. S. from the University of British Columbia, and a Ph. D. from the University of Birmingham in England in From 1990 to 2004, he served on the faculty of the Department of Chemistry, University of Massachusetts Dartmouth and received the Teacher-Scholar Award and the Scholar-Fellow Award from the Camille and Henry Dreyfus Foundation. Dr. Hammond was a Fulbright Scholar in the Department of Pharmacy, School of Chemistry, Universidad Nacional Autonoma de Mexico in Last year, he was appointed Professor of Chemistry at the University of Louisville where his research interests are focused on organofluorine chemistry and plant medicinal natural products.
John O. Trent, Ph.D.
Dr. Trent received his early training in organic chemistry graduating from the University of Canterbury, Christchurch, New Zealand and then conducted post-doctoral research in drug design at the University of Geneva in Switzerland. He then joined the Institute of Cancer Research, London, as a member of the faculty, where he was part of an internationally regarded team designing drugs to target proteases. In 1997, he joined the faculty of the University of Alabama, Birmingham, where he continued to exploit his expertise in cancer drug design. Currently, he is a member of the faculties of Chemistry, Biochemistry and Medicine and serves as the Director of the Molecular Modeling Core Facility. In addition, he is leading the Drug Discovery Program for the J. Graham Brown Cancer Center.
Hormone Receptor Laboratory